Invigo Therapeutics: what changed
Invigo Therapeutics
Largest movements
- Cash +€1,107
up €1,107 (+117%), from €946 to €2,053
mainly Net result for the year (+€9,011)
- Profit (loss) carried forward +€9,011
up €9,011 (+53.1%), from -€16,956 to -€7,945
- Trade debts -€7,277
down €7,277 (-100%), from €7,277 to €0
- Tax, wage and social debts -€627
down €627 (-100%), from €627 to €0
- Gross operating margin +€16,978
up €16,978, from -€7,311 to €9,667
- Depreciation -€9,069
down €9,069 (-100%), from €9,069 to €0
- Other operating charges +€434
up €434 (+265%), from €164 to €598
Change in the result, 2025 to 2026
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2025 and 2026 balance sheets and the 2026 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €948 | €2,055 | +€1,107 | +117% |
| Fixed assets | 21/28 | €2 | €2 | = | 0.0% |
| Intangible fixed assets | 21 | €2 | €2 | = | 0.0% |
| Current assets | 29/58 | €946 | €2,053 | +€1,107 | +117% |
| Cash at bank and in hand | 54/58 | €946 | €2,053 | +€1,107 | +117% |
| Total equity and liabilities | 10/49 | €948 | €2,055 | +€1,107 | +117% |
| Equity | 10/15 | -€6,956 | €2,055 | +€9,011 | |
| Contributions | 10/11 | €10,000 | €10,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€16,956 | -€7,945 | +€9,011 | +53.1% |
| Amounts payable | 17/49 | €7,904 | €0 | -€7,904 | -100% |
| Amounts payable within one year | 42/48 | €7,904 | €0 | -€7,904 | -100% |
| Trade debts | 44 | €7,277 | €0 | -€7,277 | -100% |
| Suppliers | 440/4 | €7,277 | €0 | -€7,277 | -100% |
| Taxes, remuneration and social security | 45 | €627 | €0 | -€627 | -100% |
| Taxes | 450/3 | €627 | €0 | -€627 | -100% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €9,069 | €0 | -€9,069 | -100% |
| Other operating charges | 640/8 | €164 | €598 | +€434 | +265% |
| Gross operating margin | 9900 | -€7,311 | €9,667 | +€16,978 | |
| Operating profit (loss) | 9901 | -€16,543 | €9,069 | +€25,612 | |
| Financial charges | 65/66B | €57 | €58 | +€1 | +1.9% |
| Recurring financial charges | 65 | €57 | €58 | +€1 | +1.9% |
| Profit (loss) for the period before taxes | 9903 | -€16,600 | €9,011 | +€25,611 | |
| Profit (loss) for the period | 9904 | -€16,600 | €9,011 | +€25,611 | |
| Profit (loss) for the period to be appropriated | 9905 | -€16,600 | €9,011 | +€25,611 |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Green is a favourable move for that line, red an unfavourable one. Prepared on 2 November 2026 via checked.be.